| 1201 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Australia
|
71 |
| 1202 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
76 |
| 1203 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Canada
|
66 |
| 1204 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
74 |
| 1205 |
Apheresis |
Allogeneic
|
Morbus Hodgkin
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
21 |
| 1206 |
Apheresis |
Allogeneic
|
Myelodysplastic Disorders
|
Hematology
|
2025
|
Standard Therapy
|
France
|
66 |
| 1207 |
Apheresis |
Allogeneic
|
Mielodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
65 |
| 1208 |
Apheresis |
Allogeneic
|
T Lymphoblastic Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Portugal
|
25 |
| 1209 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Romania
|
29 |
| 1210 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
France
|
37 |
| 1211 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
49 |
| 1212 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
32 |
| 1213 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
72 |
| 1214 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
43 |
| 1215 |
Apheresis |
Allogeneic
|
Hodking lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Serbia
|
32 |
| 1216 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Canada
|
66 |
| 1217 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
71 |
| 1218 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
66 |
| 1219 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
68 |
| 1220 |
Apheresis |
Allogeneic
|
OMDS/ Myeloproliferative Neoplasie
|
Hematology
|
2025
|
Standard Therapy
|
Switzerland
|
46 |
| 1221 |
Apheresis |
Allogeneic
|
Myelofibrosis Myeloid Metaplasia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
3 |
| 1222 |
Apheresis |
Allogeneic
|
Myelofibrosis Myeloid Metaplasia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
75 |
| 1223 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
58 |
| 1224 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Greece
|
63 |
| 1225 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
64 |
| 1226 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
65 |
| 1227 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Spain
|
49 |
| 1228 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
30 |
| 1229 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
66 |
| 1230 |
Apheresis |
Allogeneic
|
Chronic Lymphocyte Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Canada
|
55 |
| 1231 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
64 |
| 1232 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
16 |
| 1233 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
73 |
| 1234 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Ukraine
|
47 |
| 1235 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
64 |
| 1236 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
France
|
67 |
| 1237 |
Apheresis |
Allogeneic
|
Other Myelofibrosis/Myelosclerosis
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
65 |
| 1238 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
58 |
| 1239 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
57 |
| 1240 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2025
|
Standard Therapy
|
RUSSIAN FEDERATION
|
22 |
| 1241 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Ukraine
|
33 |
| 1242 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Slovakia
|
41 |
| 1243 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Greece
|
54 |
| 1244 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Ukraine
|
46 |
| 1245 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Argentina
|
26 |
| 1246 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
70 |
| 1247 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
59 |
| 1248 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
34 |
| 1249 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2025
|
Standard Therapy
|
Norway
|
53 |
| 1250 |
Apheresis |
Allogeneic
|
Other Immune System
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
19 |
| 1251 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
6 |
| 1252 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
68 |
| 1253 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
72 |
| 1254 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
64 |
| 1255 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
United Kingdom
|
33 |
| 1256 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Italy
|
63 |
| 1257 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Lithuania
|
33 |
| 1258 |
Apheresis |
Autologous
|
Central Nervous System Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
61 |
| 1259 |
Apheresis |
Allogeneic
|
Acute lymphocytic leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
51 |
| 1260 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
64 |
| 1261 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
54 |
| 1262 |
Apheresis |
Autologous
|
Testicular tumor
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
42 |
| 1263 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
52 |
| 1264 |
Apheresis |
Autologous
|
T-cell lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
49 |
| 1265 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
73 |
| 1266 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
62 |
| 1267 |
Apheresis |
Autologous
|
Lymphoma Hodgkin
|
Hematology
|
2025
|
Standard Therapy
|
Portugal
|
39 |
| 1268 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
60 |
| 1269 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
70 |
| 1270 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
64 |
| 1271 |
Apheresis |
Autologous
|
T-Cell Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
60 |
| 1272 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
62 |
| 1273 |
Apheresis |
Autologous
|
Mantle Cell Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
60 |
| 1274 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
43 |
| 1275 |
Apheresis |
Allogeneic
|
Myeofibrosis
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
37 |
| 1276 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Russia
|
22 |
| 1277 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
NETHERLANDS
|
66 |
| 1278 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
France
|
57 |
| 1279 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
United Kingdom
|
56 |
| 1280 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
78 |
| 1281 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
65 |
| 1282 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
53 |
| 1283 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Portugal
|
41 |
| 1284 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
United Kingdom
|
56 |
| 1285 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
22 |
| 1286 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
36 |
| 1287 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Canada
|
65 |
| 1288 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
71 |
| 1289 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Sweden
|
73 |
| 1290 |
Apheresis |
Allogeneic
|
NK LGL Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
42 |
| 1291 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Italy
|
29 |
| 1292 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
71 |
| 1293 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
68 |
| 1294 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Czechia
|
64 |
| 1295 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
10 |
| 1296 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Brazil
|
57 |
| 1297 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Lithuania
|
21 |
| 1298 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Lithuania
|
54 |
| 1299 |
Apheresis |
Allogeneic
|
Richter Transformation From CLL
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
55 |
| 1300 |
Apheresis |
Allogeneic
|
Richter Transformation From CLL
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
63 |